Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 2:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 75 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Dementia in Parkinsons Disease Clear all
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Evaluating the Efficacy and Safety of PROSOMNIA Sleep Therapy™ in Patients With Sleep Deprivation and Chronic Insomnia

NCT06644573
View directory record Official record
Conditions
Chronic Insomnia, Sleep Deprivation, REM Behavior Disorder, REM Sleep Behavior Disorder, REM Sleep Measurement, Insomnia, Insomnia Related to Specified Disorder, Insomnia Due to Other Mental Disorder, Insomnia Comorbid to Psychiatric Disorder, Insomnia Due to Anxiety and Fear, Insomnia Related to Another Mental Condition, Insomnia Disorders, Idiopathic Hypersomnia, Sleep Disorders, Circadian Rhythm, Post Trauma Nightmares, PTSD - Post Traumatic Stress Disorder, Sleep Quality, Anesthesia, Anxiety, Depression, Mental Health, Alzheimer Disease or Associated Disorder, Parkinsons, Circadian Rhythm, Circadian Dysregulation, PTSD, Post-Traumatic, Post-Traumatic Stress Disorder Complex, Military Combat Stress Reaction, Sleep, Military Activity, Veterans, Shift Work Sleep Disorder, Menopause Related Conditions, Pain, Cancer Pain, Athletes
Interventions
PROSOMNIA Sleep Therapy™ (PSTx), Anesthesia-Induced Sleep Therapy, Diprivan (propofol), Astra-Zeneca, Continuous EEG Monitoring
Procedure · Drug · Device
Lead sponsor
Nyree Penn
Industry
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated May 27, 2025 · Synced Jun 10, 2026, 2:22 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate a Potential PET Radioligand for Imaging Alpha-synuclein Deposits in the Brain

NCT06445465
View directory record Official record
Conditions
Alpha-Synucleinopathy, Parkinson's Disease, Dementia With Lewy Bodies, Multisystem Atrophy
Interventions
[18F]MNI-1216
Drug
Lead sponsor
Invicro
Other
Eligibility
21 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Jun 10, 2026, 2:22 AM EDT
Withdrawn No phase listed Observational

A Pilot Study to Explore the Role of Gut Flora in Parkinson's Disease

NCT04148326
View directory record Official record
Conditions
Parkinson Disease, Parkinsons Disease With Dementia, Parkinson-Dementia Syndrome, Parkinson Disease 2, Parkinson Disease 3, Parkinson Disease 4
Interventions
No Intervention
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Jun 10, 2026, 2:22 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Imaging Studies of Cognitive Impairment in Parkinson s Disease

NCT01862744
View directory record Official record
Conditions
Parkinson Disease, Dementia
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
40 Years and older
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Jun 10, 2026, 2:22 AM EDT
Recruiting No phase listed Observational

Modifiable Variables in Parkinsonism (MVP)

NCT02194816
View directory record Official record
Conditions
Parkinson's Disease, Parkinsonism, MSA - Multiple System Atrophy, Progressive Supranuclear Palsy, Shy-Drager Syndrome, Corticobasal Degeneration, Dementia With Lewy Bodies, Pick Disease, Olivopontocerebellar Atrophies
Interventions
Not listed
Lead sponsor
Bastyr University
Other
Eligibility
19 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2030
U.S. locations
1
States / cities
Kenmore, Washington
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Jun 10, 2026, 2:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Research Involving Subjects With Parkinson's Disease, Alzheimer Disease and Healthy Controls

NCT01461109
View directory record Official record
Conditions
Parkinson Disease, Alzheimer Disease
Interventions
[18F] CFPyPB
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
18 Years to 90 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 3, 2014 · Synced Jun 10, 2026, 2:22 AM EDT
Completed Not applicable Interventional Results available

Memantine for Treatment of Cognitive Impairment in Patients With Parkinson's Disease and Dementia

NCT00294554
View directory record Official record
Conditions
Parkinson's Disease, Cognitive Impairment, Dementia
Interventions
Memantine, Placebo Oral Tablet
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Jun 10, 2026, 2:22 AM EDT
Completed Not applicable Interventional

Laughter Therapy Effects on Mood, Stress and Self-efficacy in People With Neurological Diseases.

NCT02750982
View directory record Official record
Conditions
Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Brain Injury, Huntington's Disease, Multiple Sclerosis, Parkinson's Disease, Stroke, Spinal Cord Injury
Interventions
Laughter Therapy
Other
Lead sponsor
Brown, Theodore R., M.D., MPH
Individual
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Jun 10, 2026, 2:22 AM EDT
Withdrawn Phase 1 Interventional

A Study to Evaluate ENT-01 for the Treatment of Parkinson's Disease Dementia

NCT03938922
View directory record Official record
Conditions
Parkinson Disease, Dementia
Interventions
Active Investigational Treatment ENT-01
Drug
Lead sponsor
Enterin Inc.
Industry
Eligibility
30 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Fresno, California • Toms River, New Jersey • Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 29, 2024 · Synced Jun 10, 2026, 2:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects

NCT02103894
View directory record Official record
Conditions
Alzheimer's Disease (AD), Parkinson's Disease (PD), Chronic Traumatic Encephalopathy (CTE), Progressive Supranuclear Palsy (PSP), Frontal Temporal Dementia (FTD), Pick's Disease, Tauopathies
Interventions
[18F]T807 ([18F]MNI-777)
Drug
Lead sponsor
Molecular NeuroImaging
Other
Eligibility
18 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Jun 10, 2026, 2:22 AM EDT
Completed Phase 2 Interventional Results available

Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)

NCT02708186
View directory record Official record
Conditions
Dementia With Lewy Bodies, REM Sleep Behavior Disorder, Parkinson's Disease Dementia
Interventions
Nelotanserin, Placebo
Drug
Lead sponsor
Axovant Sciences Ltd.
Industry
Eligibility
50 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
23
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated May 19, 2020 · Synced Jun 10, 2026, 2:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Nilotinib in Cognitively Impaired Parkinson Disease Patients 001

NCT02281474
View directory record Official record
Conditions
Parkinson's Disease, Parkinson's Disease Dementia, Diffuse Lewy Body Disease
Interventions
Nilotinib
Drug
Lead sponsor
Georgetown University
Other
Eligibility
40 Years to 90 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 15, 2015 · Synced Jun 10, 2026, 2:22 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Reducing Caregiver Stress and Sleep Disturbances in Patients With Progressive Dementia

NCT00178568
View directory record Official record
Conditions
Sleep Disorders
Interventions
Stress Management and Healthy Sleep Practices
Behavioral
Lead sponsor
Kathy Kennedy
Other
Eligibility
60 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Jun 10, 2026, 2:22 AM EDT
Completed Phase 2 Interventional

Study Evaluating Nelotanserin for Treatment of Visual Hallucinations in Subjects With Lewy Body Dementia

NCT02640729
View directory record Official record
Conditions
Lewy Body Dementia, Visual Hallucinations
Interventions
Nelotanserin, Placebo
Drug
Lead sponsor
Axovant Sciences Ltd.
Industry
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
10
States / cities
Fountain Valley, California • Boca Raton, Florida • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Jun 10, 2026, 2:22 AM EDT
Completed Phase 3 Interventional

Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)

NCT00056524
View directory record Official record
Conditions
Alzheimer's Disease, Stroke, Parkinson's Disease, Traumatic Brain Injury
Interventions
AVP-923
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
39
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Jun 10, 2026, 2:22 AM EDT
Completed Not applicable Interventional Results available

Cognitive Dysfunction in Parkinson's Disease

NCT02346708
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Real TMS, Sham TMS
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 8, 2021 · Synced Jun 10, 2026, 2:22 AM EDT
Completed Phase 2 Interventional Results available

Study Assessing Efficacy and Safety of AKST4290 in Subjects With Parkinson's Disease on Stable Dopaminergic Treatment

NCT04369430
View directory record Official record
Conditions
Parkinson Disease
Interventions
AKST4290, Placebo
Drug
Lead sponsor
Alkahest, Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Atlanta, Georgia • West Bloomfield, Michigan • Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Oct 9, 2022 · Synced Jun 10, 2026, 2:22 AM EDT
Withdrawn Not applicable Interventional

Treating Sleep/Wake Cycle Disturbances in Basal Ganglia Disorders With Ramelteon

NCT00907595
View directory record Official record
Conditions
Huntington's Disease, Parkinson's Disease, Dementia With Lewy Bodies, Sleep Disorders, Circadian Dysregulation
Interventions
Ramelteon, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
20 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 5, 2012 · Synced Jun 10, 2026, 2:22 AM EDT
Completed Phase 3 Interventional Results available

Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD)

NCT00623103
View directory record Official record
Conditions
Parkinson's Disease Dementia
Interventions
Rivastigmine capsule, Rivastigmine transdermal patch
Drug
Lead sponsor
Novartis
Industry
Eligibility
50 Years to 85 Years
Enrollment
583 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
17
States / cities
Birmingham, Alabama • Phoenix, Arizona • Reseda, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2011 · Synced Jun 10, 2026, 2:22 AM EDT
Terminated Phase 2 Interventional

Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder

NCT02871427
View directory record Official record
Conditions
Lewy Body Dementia, Dementia With Lewy Bodies, Parkinson's Disease Dementia, Visual Hallucinations, REM Sleep Behavior Disorder
Interventions
Nelotanserin
Drug
Lead sponsor
Axovant Sciences Ltd.
Industry
Eligibility
50 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
19
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Boca Raton, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Jun 10, 2026, 2:22 AM EDT
Terminated Phase 2 Interventional Results available

ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies (SHAPE Trial)

NCT04831281
View directory record Official record
Conditions
Parkinson Disease Dementia, Dementia With Lewy Bodies
Interventions
ATH-1017, Placebo
Drug
Lead sponsor
LeonaBio
Industry
Eligibility
40 Years to 85 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
10
States / cities
Boca Raton, Florida • West Palm Beach, Florida • Decatur, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Jun 10, 2026, 2:22 AM EDT
Completed Phase 2 Interventional Results available

A Study of CST-2032 and CST-107 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's or Alzheimer's Disease

NCT05104463
View directory record Official record
Conditions
Mild Cognitive Impairment, Dementia
Interventions
CST-2032, matching placebo for CST-2032, CST-107, matching placebo for CST-107
Drug
Lead sponsor
CuraSen Therapeutics, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
14
States / cities
Scottsdale, Arizona • Lafayette, California • Boca Raton, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Jun 10, 2026, 2:22 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Connecting the Lab to Everyday Life: The Relevance of Executive Dysfunction to Participation and Quality of Life in Parkinson's Disease (PD) Without Dementia

NCT00917280
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
40 Years to 70 Years
Enrollment
174 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Jun 10, 2026, 2:22 AM EDT
Completed No phase listed Observational Results available

Amyloidopathy, Cholinopathy, Dopamine Responsiveness and Freezing of Gait in PD

NCT03647137
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Detailed motor testing, including FoG, in PD subjects
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 4, 2024 · Synced Jun 10, 2026, 2:22 AM EDT